# Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

> **NCT04382053** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 143 (actual)

## Conditions studied

- COVID-19 Pneumonia, Impaired Respiratory Function

## Interventions

- **DRUG:** DFV890
- **DRUG:** Standard of Care (SoC)

## Key facts

- **NCT ID:** NCT04382053
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-27
- **Primary completion:** 2020-12-10
- **Final completion:** 2020-12-24
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382053, "Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04382053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*